AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03069690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HABITpost
Description: Treatment during the postpartum period (HABITpost) will consist of an intervention over the 24 weeks immediately following delivery. Treatment will include 12 biweekly sessions completed over the phone or in person. In person sessions will be done at the participant's home or another convenient location. Additionally, participants will receive calls and texts between sessions. Sessions will focus on weight, physical activity, eating and psychosocial issues.~Due to COVID-19 restrictions and safety guidelines, HABIT post treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020.
Study NCT00079547 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-calorie diet
Description: low-calorie diet
Study NCT00079547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low-carbohydrate diet
Description: low-carbohydrate diet
Study NCT03009110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prophylactic NPWT
Description: The Prevena NPWT system is a small, lightweight, portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary foam and adhesive dressing. It is supplied as a pump with a sterile dressing kit and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 13 to 20 cm and more. The pump maintains negative pressure of -125 mmHg to the wound surface. The device is placed after skin closure.
Study NCT03009110 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dressing
Description: Standard wound dressing is routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
Study NCT04596878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2
Description: GBS-NN/NN2 bound to Alhydrogel as an adjuvant.
Study NCT04596878 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline 0.9%
Study NCT02029924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro
Description: Single dose of 0.2 U/Kg body weight injected subcutaneously (under the skin)
Study NCT02029924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Single dose of 0.2 /Kg body weight injected subcutaneously (under the skin)
Study NCT03741959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Active self-correction exercises (20 minutes) to achieve the best possible trunk alignment the patient can achieve in the three-dimensional planes using visual, proprioceptive and EMG feedbacks.~Passive and active trunk stabilization exercises (20 minutes) to improve trunk biomechanical constraint Functional tasks (20 minutes) defined as functional exercises to train the automatic response to maintain the best alignment through the broadest possible range of challenging activities (Romano2015).
Study NCT03741959 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Training consisted of passive and active trunk mobilization (10 minutes) followed by muscle stretching, and strengthening exercises, and gait training (50 minutes)(Bartolo et. al., 2010).
Study NCT02488512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-DOTATOC
Description: Each patient will receive a maximum cumulative 90Y-DOTATOC activity of 11.1 GBq (300 mCi) \[45-46\], divided into 4 cycles (1.8 - 2.8 GBq for each cycle) with an interval of 6 - 8 weeks between cycles. The activity to be administered will be measured in a dose calibrator, properly calibrated for the 90Y-radionuclide.
Study NCT02155439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: antimitotic drug
Study NCT02155439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Study NCT02143622 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LJM716
Description: antibody
Study NCT02143622 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: antibody
Study NCT01804556 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Myofascial trigger point injections on gastrocnemius muscle
Description: On the first visit (T0), we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index using questionnaires. Then we check trigger points of gastrocnemius muscle and inject lidocaine 1 \~ 2 ml each up to four points. One week later (T1) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index again, check trigger points, and if any, inject lidocaine. If the patient do not come, we get numeric rating scale (NRS), the frequency of cramps and insomnia severity index over the telephone. Two weeks after the first visit (T2), we repeat the procedure of the first visit (T0). And four weeks after the first visit (T3) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index through face-to-face interview or by telephone.
Study NCT02047617 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: the standard physiotherapy group
Description: Mobilization and rehabilitation program is progressively introduced after clinical stabilization
Study NCT02047617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standing table group
Description: The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform
Study NCT03895853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care
Study NCT03895853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care
Study NCT03895853 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: early metabolic resuscitation
Description: Given Intravenous
Study NCT02096055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study NCT03474640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part A
Description: Part A: 80, 240, and 480 mg IV every 14 days.
Study NCT03474640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Part B
Description: Part B: 240 mg IV every 3 weeks
Study NCT03203265 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group A: Offline HTC
Description: Offline or online referral to HIV treatment facility HIV-positive participants can choose to receive either an offline or online referral to HIV treatment facilities. An offline referral method usually includes a referral letter and/or a telephone call, followed by a series of calls to participants to ensure successful referral. Those who choose an online referral will be able to register online with an HIV treatment facility which provides ART without cost under the national programs. Participants will receive a registration code which will allow them to access HIV treatment clinics directly without the need to go through the regular registration and appointment system at that facility.
Study NCT03203265 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group B1: Offline HIV testing and post-test counseling
Description: participants will be guided to access services at the 'Adam's Love Offline Clinic,' a clinic set up specifically to provide private and fast HIV testing and post-test counseling only referred from the Adam's Love Online Clinic.
Study NCT03203265 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group B2: Online HIV testing and post-test counseling
Description: A trained online counselor will guide the participant through an online HIV testing process which includes quality checking of the test kit,obtaining blood through finger prick,performing the testing steps,reading the test result. A positive result from the first test will trigger the need for referral to confirmatory tests. The provisional nature of the positive result from the single rapid HIV test will be emphasized but the urgency to get immediate confirmatory tests and linkage to HIV treatment facilities will encouraged and supported. HIV positive test result will be confirmed only with three positive tests. Any online testing session with uncertain qualities at any step will be repeated at a later time or the participant will be offered offline HIV testing.
Study NCT04175691 — intervention group
Intervention type: GENETIC
Intervention: Sequencing of circRNA/miRNA/lncRNA
Description: Next generation sequencing of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA)
Study NCT04234516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/Naloxone 8/2 milligram (mg) Sublingual Film
Description: 3 x 8 mg sublingual buprenorphine/naloxone films wrapped inside one Listerine strip at 8 pm daily + oral placebo pills q.i.d.
Study NCT04234516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate 30 mg
Description: oral morphine sulphate 30 mg immediate release tablets q.i.d. + two sublingual Listerine strips at 8 pm
Study NCT02810496 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood collection for mutation characterization
Study NCT03877848 — intervention group
Intervention type: DEVICE
Intervention: Percutaneous Coronary Intervention (PCI)
Description: Patients enrolled to the study will undergo angiography followed by PCI according to current guidelines.
Study NCT00568516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3550
Description: subcutaneous administration
Study NCT03681769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS to the left dlPFC
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the Universal Serial Bus (USB) key).
Study NCT03681769 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS to the left dlPFC
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
Study NCT03681769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cTBS to the mPFC
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
Study NCT03681769 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cTBS to the mPFC
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
Study NCT00070707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone
Description: Mometasone nasal spray 200 mcg/day administered as 2 sprays (50 mcg/spray) in each nostril.
Study NCT00070707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo nasal spray, administered QD as 2 sprays in each nostril.
Study NCT00070707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol
Description: Albuterol/salbutamol metered dose inhaler (90 mcg/puff) used as needed as asthma rescue medication.
Study NCT00070707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/Salbutamol
Description: Albuterol/salbutamol metered dose inhaler (90 mcg/puff) used as needed as asthma rescue medication.
Study NCT01114386 — intervention group
Intervention type: PROCEDURE
Intervention: Lung function testing, echocardiography, blood sampling
Description: All patients will undergo to:~* physical examination~* 6' Minute Walk test~* pulmonary function testing (spirometry + volumes and reversibility testing)~* carbon monoxide diffusing capacity (DLCO) with single-breathe technique~* ECG~* echocardiography
Study NCT02780817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Error enhancement
Description: Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device, followed by one game with null force field, followed by 5 games as the main intervention with error enhancement force field, and another last game with null force field.
Study NCT02780817 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device and another 7 games with null force field.
Study NCT03372772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Description: Levocarnitine syrup- Oral supplementation about 2000mg/ day for 8 weeks
Study NCT03590691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vietnam National Hypertension Program
Description: A training program for health care workers including physicians and nurses and a health educational program for general public regarding hypertension management at community level will be implemented
Study NCT03590691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vietnam National Hypertension Program
Description: A training program for health care workers including physicians and nurses and a health educational program for general public regarding hypertension management at community level will be implemented
Study NCT03590691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expanded community health worker services
Description: A training program will be implemented for community health workers regarding hypertension management at community level so that they can assist patients better manage their blood pressure at home.
Study NCT03590691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling intervention
Description: The storytelling intervention consists of interactive, literacy-appropriate, and culturally sensitive multimedia storytelling modules for motivating behavior change through the power of patients speaking in their own voice. Based on preferences that emerged during the researchers' formative work with the partnering rural communities, the storytelling intervention will be delivered by DVD, with serial installments at baseline and at 3, 6, and 12 months after trial enrollment.
Study NCT03590691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home blood pressure self-monitoring
Description: Patients with hypertension will be provided blood pressure monitors and guided to self-measure their blood pressure and to record their blood pressure daily at home.
Study NCT04440631 — intervention group
Intervention type: OTHER
Intervention: no intervention, observational only
Description: no intervention, observational only
Study NCT01257737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPN-100
Description: Participants received individualized doses of HPN-100 orally, three times daily (TID) with meals. The initial dose was the same dose administered at the end of the HPN-100-005SE, HPN-100-007, or HPN-100-012SE studies. Dose adjustments (including frequency adjustments) were permitted as judged clinically appropriate by the investigator based on assessment of ammonia-scavenging needs (e.g., severity of the UCD defect, dietary protein intake, and urinary phenylacetylglutamine \[PAGN\] excretion). The maximum recommended dose of HPN-100 in participants weighing less than 20 kg was 0.53 mL/kg/day (equivalent to 600 mg/kg/day of NaPBA), and was 11.48 mL/m²/day in heavier subjects (equivalent to 13g/m²/day of NaPBA). The maximum HPN-100 dose recommended per protocol was 17.4 mL/day, which is equivalent to 20 g/day of NaPBA.
Study NCT02096055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC
Study NCT02096055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV
Study NCT03433456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visitation + HABITS program
Description: The HABITS program will target 5 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, decreasing fried foods, and encouraging regular self-monitoring and self-weighing) aimed at reducing obesity risk in mothers or primary caregivers and children.
Study NCT03433456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard home visitation program
Description: Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on promoting caregiver and child health by providing screenings and referrals, encouraging smoking cessation, promoting safe sleep practices, and strengthening children's school readiness and achievement, social/emotional and physical development.
Study NCT03433456 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard home visitation program
Description: Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on promoting caregiver and child health by providing screenings and referrals, encouraging smoking cessation, promoting safe sleep practices, and strengthening children's school readiness and achievement, social/emotional and physical development.
Study NCT04749121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVC Irradiation
Description: We used the Porcine epidemic diarrhea virus (PEDV) as the indicator virus .An N99 mask was contaminated by spraying or applying with the virus on the exterior and interior surface of each silicone mask. Also, 100 μl of the viral suspension was spotted onto the filter part of N99 masks. Following 20-30 minutes of drying, the silicone masks underwent each of the decontamination procedures which are ultraviolet-C (UV-C) irradiation and 70% alcohol treatment. For UV irradiation, N99 masks were placed in an UV-C incubator ) and were exposed for different times at 1, 10 and 20 minutes, respectively.Untreated control and treated N99 masks were analyzed for viral infectivity in VERO cell cultures. At 48 hours post-infection, cells were examined for evaluation the viral infectivity via observation of cytopathic effect. Results for each treatment express mean ± standard deviations of 3 biological replicates.
Study NCT04749121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UVC Irradiation
Description: Bacterial and fungal sampling were obtained from the inside and outside surface areas likely to the frequently touched and close contact with the face of hospital personnel. The cultures were then isolated onto the blood agars and Mac Conkey agars, respectively. After incubation, the total number of bacterial and fungal colonies were counted, recorded, and selected different colonies.
Study NCT04749121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fit test
Description: All the participants had to pass the initial fit test.After decontamination with UVC irradiation for 60 minutes, fit testing was conducted using qualitative fit test (Bittrex Solution aerosol),
Study NCT04749121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tensile strength
Description: We measured the tensile strength of the strap of the Silicone mask before and after the UVC irradiation to study the strength and reliliency of the strap
Study NCT03943199 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual Analogue Scale for pain
Description: Will be assessed at 0´, 30´, 60´, 90 minutes and 18 hours after the application of the analgesic.
Study NCT03943199 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Visual Analogue Scale for pain
Description: Will be assessed at 0´, 30´, 60´, 90 minutes and 18 hours after the application of the analgesic.
Study NCT02265640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS boli
Study NCT02265640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIIL 284 BS tablet C
Study NCT02265640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard breakfast
Study NCT02265640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard breakfast
Study NCT01455675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IgY
Description: Avian polyclonal anti-pseudomonas antibodies (IgY)
Study NCT01455675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 70 ml gargling solution, once daily
Study NCT02675452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 176
Description: Study Drug
Study NCT02675452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Non-investigational product
Study NCT02675452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Non-investigational product
Study NCT00886093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: 35 mg tablet of PF-04447943 taken in the fed state in Period 1 followed a week later by administration of the same tablet and dose taken in the fasted state in Period 2
Study NCT00886093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: 35 mg tablet of PF-04447943 taken in the fasted state in Period 1 followed a week later by administration of the same tablet and dose in the fed state in Period 2.
Study NCT01637207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palpation
Description: Group A: Palpation Group
Study NCT01637207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Group B: Ultrasound Group